381 related articles for article (PubMed ID: 28658983)
1. Melphalan hydrochloride for the treatment of multiple myeloma.
Esma F; Salvini M; Troia R; Boccadoro M; Larocca A; Pautasso C
Expert Opin Pharmacother; 2017 Aug; 18(11):1127-1136. PubMed ID: 28658983
[TBL] [Abstract][Full Text] [Related]
2. Melphalan Flufenamide (Melflufen): First Approval.
Dhillon S
Drugs; 2021 Jun; 81(8):963-969. PubMed ID: 33961277
[TBL] [Abstract][Full Text] [Related]
3. Melflufen for relapsed and refractory multiple myeloma.
Oriol A; Larocca A; Leleu X; Hajek R; Hassoun H; Rodríguez-Otero P; Paner A; Schjesvold FH; Gullbo J; Richardson PG
Expert Opin Investig Drugs; 2020 Oct; 29(10):1069-1078. PubMed ID: 32924646
[TBL] [Abstract][Full Text] [Related]
4. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
[TBL] [Abstract][Full Text] [Related]
5. Bendamustine in the treatment of multiple myeloma: results and future perspectives.
Pönisch W; Niederwieser D
Semin Oncol; 2002 Aug; 29(4 Suppl 13):23-6. PubMed ID: 12170429
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two melphalan protocols and evaluation of outcome and prognostic factors in multiple myeloma in dogs.
Fernández R; Chon E
J Vet Intern Med; 2018 May; 32(3):1060-1069. PubMed ID: 29566439
[TBL] [Abstract][Full Text] [Related]
7. Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma.
Raaijmakers HG; Izquierdo MA; Lokhorst HM; de Leeuw C; Belien JA; Bloem AC; Dekker AW; Scheper RJ; Sonneveld P
Blood; 1998 Feb; 91(3):1029-36. PubMed ID: 9446666
[TBL] [Abstract][Full Text] [Related]
8. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
9. [High-dose melphalan in patients with multiple myeloma].
Moreau P; Le Bonniec M; Harousseau JL
Bull Cancer; 1999 Mar; 86(3):283-8. PubMed ID: 10210762
[TBL] [Abstract][Full Text] [Related]
10. Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study.
Cooper MR; McIntyre OR; Propert KJ; Kochwa S; Anderson K; Coleman M; Kyle RA; Prager D; Rafla S; Zimmer B
J Clin Oncol; 1986 Sep; 4(9):1331-9. PubMed ID: 3528403
[TBL] [Abstract][Full Text] [Related]
11. Melphalan and its role in the management of patients with multiple myeloma.
Falco P; Bringhen S; Avonto I; Gay F; Morabito F; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2007 Jul; 7(7):945-57. PubMed ID: 17627453
[TBL] [Abstract][Full Text] [Related]
12. Treatment of myeloma: recent developments.
Zweegman S; Huijgens PC
Anticancer Drugs; 2002 Apr; 13(4):339-51. PubMed ID: 11984079
[TBL] [Abstract][Full Text] [Related]
13. Melphalan kinetics in hyperthermic isolation perfusion of the extremities.
Loos U; Musch E; Rauschecker H; Willenbrock C
J Chemother; 1989 Jul; 1(4 Suppl):1246-7. PubMed ID: 16312851
[No Abstract] [Full Text] [Related]
14. Treatment of multiple myeloma in patients with Gaucher disease.
Machaczka M; Lerner R; Klimkowska M; Hägglund H
Am J Hematol; 2009 Oct; 84(10):694-6. PubMed ID: 19743447
[No Abstract] [Full Text] [Related]
15. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
[TBL] [Abstract][Full Text] [Related]
16. [High-dose melphalan with stem cell support is now an established myeloma therapy. Treatment of myeloma from a 30-year perspective].
Hjorth M; Lenhoff S; Turesson I; Westin J
Lakartidningen; 2000 Oct; 97(41):4585-6, 4589-92. PubMed ID: 11107744
[TBL] [Abstract][Full Text] [Related]
17. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.
Terpos E; Kastritis E; Roussou M; Heath D; Christoulas D; Anagnostopoulos N; Eleftherakis-Papaiakovou E; Tsionos K; Croucher P; Dimopoulos MA
Leukemia; 2008 Dec; 22(12):2247-56. PubMed ID: 18769451
[TBL] [Abstract][Full Text] [Related]
18. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
[TBL] [Abstract][Full Text] [Related]
19. [Therapy of multiple myeloma].
La Verde G; Pulsoni A; Petrucci MT; Mandelli F
Recenti Prog Med; 1997 Apr; 88(4):186-93. PubMed ID: 9206817
[TBL] [Abstract][Full Text] [Related]
20. Autologous transplantation and maintenance therapy in multiple myeloma.
Palumbo A; Cavallo F; Gay F; Di Raimondo F; Ben Yehuda D; Petrucci MT; Pezzatti S; Caravita T; Cerrato C; Ribakovsky E; Genuardi M; Cafro A; Marcatti M; Catalano L; Offidani M; Carella AM; Zamagni E; Patriarca F; Musto P; Evangelista A; Ciccone G; Omedé P; Crippa C; Corradini P; Nagler A; Boccadoro M; Cavo M
N Engl J Med; 2014 Sep; 371(10):895-905. PubMed ID: 25184862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
